Vanda Pharmaceuticals, Inc. (VNDA) Misses Q1 EPS by 49c
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.53 +2.03%
Revenue Growth %: +24.1%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +24.1%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q1 EPS of ($0.79), $0.49 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.75 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- Broadcom (AVGO) Tops Q3 EPS by 11c, Offers Guidance
- Five Below (FIVE) Tops Q2 EPS by 35c, Beats on Revenue; Offers Q3 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
